Ferroptosis and PPAR-gamma in the limelight of brain tumors and edema

Abstract

Human malignant brain tumors such as gliomas are devastating due to the induction of cerebral edema and neurodegeneration. A major contributor to glioma-induced neurodegeneration has been identified as glutamate. Glutamate promotes cell growth and proliferation in variety of tumor types. Intriguently, glutamate is also an excitatory neurotransmitter and evokes neuronal cell death at high concentrations. Even though glutamate signaling at the receptor and its downstream effectors has been extensively investigated at the molecular level, there has been little insight into how glutamate enters the tumor microenvironment and impacts on metabolic equilibration until recently. Surprisingly, the 12 transmembrane spanning tranporter xCT (SLC7A11) appeared to be a major player in this process, mediating glutamate secretion and ferroptosis. Also, PPARγ is associated with ferroptosis in neurodegeneration, thereby destroying neurons and causing brain swelling. Although these data are intriguing, tumor-associated edema has so far been quoted as of vasogenic origin. Hence, glutamate and PPARγ biology in the process of glioma-induced brain swelling is conceptually challenging. By inhibiting xCT transporter or AMPA receptors in vivo, brain swelling and peritumoral alterations can be mitigated. This review sheds light on the role of glutamate in brain tumors presenting the conceptual challenge that xCT disruption causes ferroptosis activation in malignant brain tumors. Thus, interfering with glutamate takes center stage in forming the basis of a metabolic equilibration approach.

Metabolic dysfunction-associated steatotic liver disease: ferroptosis related mechanisms and potential drugs

“…This dual regulatory function of p53 holds great potential for cancer treatment (Kang et al, 2019). Additionally, ROS accumulation induces endoplasmic reticulum stress, affecting the activity of peroxisome proliferator-activated receptor (PPAR) (Yakubov et al, 2023) and influencing iron metabolism through inflammatory signaling pathways (Cheng et al, 2021a;Zhao et al, 2023). Moreover, as research progresses, emerging potential targets and receptors are being identified.…”